Results 1 to 10 of about 8,801 (259)

Platelets modulate cardiac remodeling via the collagen receptor GPVI after acute myocardial infarction [PDF]

Frontiers in Immunology, 2023
IntroductionPlatelets play an important role in cardiovascular diseases. After acute myocardial infarction, platelets display enhanced activation and migrate into the infarct zone.
Friedrich Reusswig, Matthias Dille, E. Krüger, J. Ortscheid, Tobias Feige, S. Gorressen, J.-W. Fischer, Margitta Elvers   +7 more
doaj   +4 more sources

GPVI inhibition:Advancing antithrombotic therapy in cardiovascular disease [PDF]

Eur Heart J Cardiovasc Pharmacother
Glycoprotein (GP) VI plays a major role in thrombosis but not haemostasis, making it a promising antithrombotic target. The primary role of GPVI on the surface of platelets is a signalling receptor for collagen, which is one of the most potent thrombotic
Khattak, Sophia, Slater, Alexandre, Thomas, Mark R   +2 more
core   +5 more sources

Immobilized collagen prevents shedding and induces sustained GPVI clustering and signaling in platelets [PDF]

Platelets, 2021
Collagen, the most thrombogenic constituent of blood vessel walls, activates platelets through glycoprotein VI (GPVI). In suspension, following platelet activation by collagen, GPVI is cleaved by A Disintegrin And Metalloproteinase (ADAM)10 and ADAM17 ...
Chiara Pallini, Jeremy A. Pike, Christopher O’Shea, Robert K. Andrews, Elizabeth E. Gardiner, Steve P. Watson, Natalie S. Poulter   +6 more
doaj   +5 more sources

Characterization of GPVI- or GPVI-CD39-Coated Nanoparticles and Their Impact on In Vitro Thrombus Formation [PDF]

International Journal of Molecular Sciences, 2021
Traditional antithrombotic agents commonly share a therapy-limiting side effect, as they increase the overall systemic bleeding risk. A novel approach for targeted antithrombotic therapy is nanoparticles. In other therapeutic fields, nanoparticles have enabled site-specific delivery with low levels of toxicity and side effects.
Jeremy Nestele, Anne‐Katrin Rohlfing, Valerie Dicenta, Alexander Bild, Daniela Eißler, Fréderic Emschermann, Marcel Kremser, Konstantin Krutzke, Tilman E. Schäffer, Oliver Borst, Moran Levi, Netanel Korin, Meinrad Gawaz   +12 more
semanticscholar   +6 more sources

Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer [PDF]

Blood Adv
Glycoprotein VI (GPVI) plays a key role in collagen-induced platelet aggregation. Affimers are engineered binding protein alternatives to antibodies. We screened and characterized GPVI-binding Affimers as novel tools to probe GPVI function.
Adams, Thomas L., Ariëns, Robert A. S., Calabrese, Antonio N., Cheah, Lih T., Duval, Cédric, Gauer, Julia S., Herr, Andrew B., Hindle, Matthew S., Naseem, Khalid M., Slater, Alexandre, Tiede, Christian, Tomlinson, Darren C., Watson, Steve P., Webb, Beth A., Xu, Rui-Gang, Yates, Daisie M.   +15 more
core   +4 more sources

Structure-function relationship of the platelet glycoprotein VI (GPVI) receptor: does it matter if it is a dimer or monomer? [PDF]

Platelets, 2021
GPVI is a critical signaling receptor responsible for collagen-induced platelet activation and a promising anti-thrombotic target in conditions such as coronary artery thrombosis, ischemic stroke, and atherothrombosis. This is due to the ability to block
Joanne C. Clark, Foteini-Nafsika Damaskinaki, Yam Fung Hilaire Cheung, Alexandre Slater, Steve P. Watson   +4 more
doaj   +3 more sources

Platelet surface receptor glycoprotein VI-dimer is overexpressed in stroke: The Glycoprotein VI in Stroke (GYPSIE) study results. [PDF]

PLoS ONE, 2022
ObjectivesPlatelet activation underpins thrombus formation in ischemic stroke. The active, dimeric form of platelet receptor glycoprotein (GP) VI plays key roles by binding platelet ligands collagen and fibrin, leading to platelet activation.
Isuru Induruwa, Harriet McKinney, Carly Kempster, Patrick Thomas, Joana Batista, Jean-Daniel Malcor, Arkadiusz Bonna, Joanne McGee, Elaine Bumanlag-Amis, Karola Rehnstrom, Sophie Ashford, Kenji Soejima, Willem Ouwehand, Richard Farndale, Kate Downes, Elizabeth Warburton, Masaaki Moroi, Stephanie Jung   +17 more
doaj   +2 more sources

Human Platelet Protein Ubiquitylation and Changes following GPVI Activation [PDF]

Thrombosis and Haemostasis, 2018
Platelet activators stimulate post-translational modification of signalling proteins to change their activity or their molecular interactions leading to signal propagation. One covalent modification is attachment of the small protein ubiquitin to lysine
Amanda J. Unsworth, Izabela Bombik, Adán Pinto-Fernández, Joanna F. McGouran, Rebecca Konietzny, René P. Zahedi, Steve P. Watson, Benedikt M. Kessler, Catherine J. Pears   +8 more
core   +11 more sources

Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice [PDF]

Blood, 2004
AbstractGlycoprotein VI (GPVI) is an essential platelet collagen receptor; therefore, the inhibition of GPVI-collagen interactions may be an attractive antithrombotic strategy. We have previously shown that targeting of GPVI with antibodies leads to the depletion of the receptor and to long-term antithrombotic protection in mice.
Sabine Grüner, Miroslava Prostredná, Martina Koch, Yoshiki Miura, Valerie Schulte, Stéphanie Jung, Masaaki Moroi, Bernhard Nieswandt   +7 more
openalex   +3 more sources

Comparison of the GPVI inhibitors losartan and honokiol [PDF]

Platelets, 2020
Losartan and honokiol are small molecules which have been described to inhibit aggregation of platelets by collagen. Losartan has been proposed to block clustering of GPVI but not to affect binding of collagen. Honokiol has been reported to bind directly
Marie-Blanche Onselaer, Magdolna Nagy, Chiara Pallini, Jeremy A Pike, Gina Perrella, Lourdes Garcia Quintanilla, Johannes A Eble, Natalie S. Poulter, Johan W.M. Heemskerk, Steve P Watson   +9 more
doaj   +4 more sources